Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

281.19-4.07 (-1.43%)

At close: 4:00PM EDT

281.30 +0.11 (+0.04%)
After hours: 07:54PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	285.26
Open	285.34
Bid	278.50 x 800
Ask	281.50 x 800
Day's Range	278.61 - 286.00
52 Week Range	223.25 - 468.55
Volume	1,299,757
Avg. Volume	965,220

Market Cap	41.907B
Beta (5Y Monthly)	0.47
PE Ratio (TTM)	22.49
EPS (TTM)	12.50
Earnings Date	Oct 20, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	397.48

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Biogen Inc.
Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Rating
Fair Value
Economic Moat
5 days agoMorningstar

All

News

Press Releases

Research Reports

Zacks
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Motley Fool
3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More
Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months. The consensus price target for Bristol Myers Squibb (NYSE: BMY) is 39% above the big drugmaker's current share price. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.
GlobeNewswire
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p